Hasegawa, Kosei Takahashi, Shunji Ushijima, Kimio Okadome, Masao Yonemori, Kan Yokota, Harushige Vergote, Ignace Monk, Bradley Tewari, Krishnansu Fujiwara, Keiichi
...
BACKGROUND: In the phase 3 EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 study, cemiplimab significantly improved overall survival (OS) versus chemotherapy for patients with recurrent or metastatic cervical cancer who progressed after first-line platinum-based chemotherapy. We present a post hoc subgroup analysis of patients enrolled in Japan. METHODS: Pat...
Zhao, Yaqi Laird, A Roberts, Kathryn Yafawi, Rolla Kantarjian, Hagop DeAngelo, Daniel Stelljes, Matthias Liedtke, Michaela Stock, Wendy Gökbuget, Nicola
...
The phase 3 INO-VATE trial demonstrated higher rates of remission, measurable residual disease negativity, and improved overall survival for patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) who received inotuzumab ozogamicin (InO) vs standard-of-care chemotherapy (SC). Here, we examined associations between genomic alterat...
Yin, Tao Mou, Shuanzhu Zhang, Haiyu Dong, Ying Yan, Bing Huang, Weisheng Liu, Yuhan Mei, Hongbing
Published in
Discover Oncology
Introduction As proteins that promote immune cell differentiation, chemokines have attracted great interest regarding their role in anti-tumor immune responses within the cancer environment. However, the exact role of CXCL10, a chemokine, in bladder cancer (BLCA) is still not fully elucidated. Method In the present study, we employed bioinformatics...
Xu, Yuanming Wen, Natalie Haddad, Robert Sonis, Stephen Villa, Alessandro
OBJECTIVES: Immune-related adverse events (irAEs) are common. Oral irAEs tend to cluster in patients who experience concurrent toxicities. We aimed to characterize the frequency and trajectory of non-oral irAEs in patients who developed oral irAEs, assess their relationship with non-oral irAEs, and compare those characteristics with patients withou...
Sharma, Rupam Orogian, Arin Garcia-Pacheco, Ralph Trang, Tung Clarke, Matthew Stull, William Kim, Stanley
Primary thyroid lymphoma is one of the rare and distinct type of extra nodal lymphomas originating within the thyroid gland. It accounts for less than 5% of all thyroid malignancies and 2% of extra nodal lymphomas. It predominantly affects older adults, with a higher incidence in women. Patients typically present with a rapidly enlarging thyroid ma...
El Zarif, Talal Nassar, Amin Pond, Gregory Zhuang, Tony Master, Viraj Nazha, Bassel Niglio, Scot Simon, Nicholas Hahn, Andrew Pettaway, Curtis
...
BACKGROUND: Treatment options for penile squamous cell carcinoma are limited. We sought to investigate clinical outcomes and safety profiles of patients with penile squamous cell carcinoma receiving immune checkpoint inhibitors. METHODS: This retrospective study included patients with locally advanced or metastatic penile squamous cell carcinoma re...
Yaqub, Atif Nasir, Muhammad Kamran, Muhammad Majeed, Iqra Arif, Aneeza
Published in
Biological trace element research
Recently some metal-based nanoparticles have gained serious attention from aquaculture and the fish feed industry as feed supplements. Oral supplementation of zinc oxide nanoparticles (ZnO-NPs) in fish feed, replacing Zn acetate (conventionally used zinc), is suggested as a cost-effective and efficient approach. Our study assessed the response of N...
Friedman, Joshua Jun, Tomi Rashidipour, Omid Huang, Kuan-Lin Ellis, Ethan Kadaba, Priyanka Belani, Puneet Nael, Kambiz Tsankova, Nadejda Sebra, Robert
...
PURPOSE: While immune checkpoint inhibitors (ICI) have had success with various malignancies, their efficacy in brain cancer is still unclear. Retrospective and prospective studies using PD-1 inhibitors for recurrent glioblastoma (GBM) have not established survival benefit. This study evaluated if ICI may be effective for select patients with recur...
Badran, Yousef R Zou, Fangwen Durbin, Sienna M Dutra, Barbara E Abu-Sbeih, Hamzah Thomas, Anusha S Altan, Mehmet Thompson, John A Qiao, Wei Leet, Donna E
...
PurposeImmune checkpoint inhibitor (ICI) therapy is often suspended because of immune-related enterocolitis (irEC). We examined the effect of resumption of ICIs with or without concurrent selective immunosuppressive therapy (SIT) on rates of symptom recurrence and survival outcomes.MethodsThis retrospective, multicenter study examined patients who ...
Salem, Joe-Elie Bretagne, Marie Abbar, Baptiste Leonard-Louis, Sarah Ederhy, Stéphane Redheuil, Alban Boussouar, Samia Nguyen, Lee S Procureur, Adrien Stein, Frederic
...
Immune-checkpoint-inhibitor (ICI)-associated myotoxicity involves the heart (myocarditis) and skeletal muscles (myositis), which frequently occur concurrently and are highly fatal. We report the results of a strategy that included identification of individuals with severe ICI myocarditis by also screening for and managing concomitant respiratory mu...